Agios Pharmaceuticals公司宣布,其针对镰状细胞病的Tebapivat二期临床试验的关键顶线数据,预计将在2026年下半年出炉。这一时间点标志着该候选疗法研发进程中的一个重要里程碑,备受业界关注。
Agios Pharmaceuticals公司宣布,其针对镰状细胞病的Tebapivat二期临床试验的关键顶线数据,预计将在2026年下半年出炉。这一时间点标志着该候选疗法研发进程中的一个重要里程碑,备受业界关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.